Products - HIV and AIDS | Topic

Showing 13 products

Date | Title

Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 January 2025
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabotegravir with rilpivirine for treating HIV-1 (TA757)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 January 2022
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2013
Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TS ID 10723]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
HIV testing: encouraging uptake (QS157)
Product type:
Quality standard
Published:
7 September 2017
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
Product type:
Guidance
Programme:
NICE guideline
Published:
1 December 2016
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lenacapavir for treating multidrug resistant HIV-1 ID6196
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Spinal Cord Stimulation Effective for HIV Neuropathy
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC

HIV and AIDS Products

Filter

Product type

Guidance programme

Status

New and updated

Showing 13 products

Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Cabotegravir with rilpivirine for treating HIV-1 (TA757)

Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]

Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)

Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TS ID 10723]

Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

HIV testing: encouraging uptake (QS157)

HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]

Lenacapavir for treating multidrug resistant HIV-1 ID6196

Spinal Cord Stimulation Effective for HIV Neuropathy